Kymera Therapeutics Inc (KYMR)
NASDAQ
News
Market Data
Register for real-time alerts, custom portfolio, and market movers
Kymera Therapeutics Inc is a biotechnology company pioneering a transformative new approach to treating previously untreatable diseases. The company is advancing the field of targeted protein degradation, accessing the body's innate protein recycling machinery to degrade dysregulated, disease-causin... Kymera Therapeutics Inc is a biotechnology company pioneering a transformative new approach to treating previously untreatable diseases. The company is advancing the field of targeted protein degradation, accessing the body's innate protein recycling machinery to degrade dysregulated, disease-causing proteins. Kymera's Pegasus targeted protein degradation platform harnesses the body's natural protein recycling machinery to degrade disease-causing proteins, with a focus on un-drugged nodes in validated pathways currently inaccessible with conventional therapeutics. It is accelerating drug discovery with an unmatched ability to target and degrade intractable proteins and advance new treatment options for patients. Show more
Ask ADVFN Intelligence (AI)
WATERTOWN, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader...
KT-621 (STAT6) Phase 1 healthy volunteer trial ongoing, with data expected in 2Q25 Kymera plans to initiate a KT-621 Phase 1b trial in atopic dermatitis (AD) patients in 2Q25 with data in 4Q25...
WATERTOWN, Mass., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader...
WATERTOWN, Mass., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using...
WATERTOWN, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using...
| Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -1.66 | -4.10992820005 | 40.39 | 41.85 | 37.875 | 376550 | 39.33006514 | CS |
| 4 | -1.535 | -3.81224388427 | 40.265 | 45.31 | 35.57 | 509992 | 40.84316375 | CS |
| 12 | -11.81 | -23.3676296003 | 50.54 | 51.05 | 35.57 | 484102 | 42.33093927 | CS |
| 26 | -0.5 | -1.2745347948 | 39.23 | 53.27 | 35.57 | 438722 | 44.72911467 | CS |
| 52 | 6.08 | 18.6217457887 | 32.65 | 53.27 | 29.24 | 532135 | 40.59302386 | CS |
| 156 | -1.15 | -2.88365095286 | 39.88 | 53.27 | 9.6 | 605478 | 29.88437522 | CS |
| 260 | 5.81 | 17.6488456865 | 32.92 | 91.92 | 9.6 | 511694 | 34.31065427 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
